rss
JAMIA 2004;11:482-491 doi:10.1197/jamia.M1556
  • Original Investigation
  • Research Paper

Characteristics and Consequences of Drug Allergy Alert Overrides in a Computerized Physician Order Entry System

  1. Tyken C Hsieh,
  2. Gilad J Kuperman,
  3. Tonushree Jaggi,
  4. Patricia Hojnowski-Diaz,
  5. Julie Fiskio,
  6. Deborah H Williams,
  7. David W Bates,
  8. Tejal K Gandhi
  1. Affiliations of the authors: Division of General Internal Medicine, Brigham and Women's Hospital, Boston, MA (TCH, PH-D, JF, DHW, DWB, TKG); Department of Clinical Practice Evaluation, New York-Presbyterian Hospital, New York, NY (GJK); The Advisory Board Company, Washington, DC (TJ)
  1. Correspondence and reprints: Tejal K. Gandhi, MD, MPH, Division of General Medicine, Brigham and Women's Hospital, 1620 Tremont Street, 3rd Floor, Boston, MA 02120; e-mail: <tgandhi{at}partners.org>
  • Received 9 February 2004
  • Accepted 14 July 2004

Abstract

Objective The aim of this study was to determine characteristics of drug allergy alert overrides, assess how often they lead to preventable adverse drug events (ADEs), and suggest methods for improving the allergy-alerting system.

Design Chart review was performed on a stratified random subset of all allergy alerts occurring during a 3-month period (August through October 2002) at a large academic hospital.

Measurements Factors that were measured were drug/allergy combinations that triggered alerts, frequency of specific override reasons, characteristics of ADEs, and completeness of allergy documentation.

Results A total of 6,182 (80%) of 7,761 alerts were overridden in 1,150 patients. In this sample, only 10% of alerts were triggered by an exact match between the drug ordered and allergy listed. Physicians' most common reasons for overriding alerts were “Aware/Will monitor” (55%), “Patient does not have this allergy/tolerates” (33%), and “Patient taking already” (10%). In a stratified random subset of 320 patients (28% of 1,150) on chart review, 19 (6%) experienced ADEs attributed to the overridden drug; of these, 9 (47%) were serious. None of the ADEs was considered preventable, because the overrides were deemed clinically justifiable. The degree of completeness of patients' allergy lists was highly variable and generally low in both paper charts and the CPOE system.

Conclusion Overrides of drug-allergy alerts were common and about 1 in 20 resulted in ADEs, but all of the overrides resulting in ADEs appeared clinically justifiable. The high rate of alert overrides was attributable to frequent nonexact match alerts and infrequent updating of allergy lists. Based on these findings, we have made specific recommendations for increasing the specificity of alerting and thereby improving the clinical utility of the drug allergy alerting system.

Footnotes

  • Supported by a grant from the National Library of Medicine (R01 LM007203) and a student research grant from Harvard Medical School.

  • The authors thank Cathy A. Foskett, RN, and Katherine R. Zigmont, RN, for their assistance with chart review and data collection; Elisabeth Burdick, MS, and Brian Chan, BS, for their assistance with the statistical analysis; and Ashish K. Jha, MD, Thomas D. Sequist, MD, Edward Lowenstein, MD, Michael T. Bailin, MD, and Maura E. LeBaron for their support and thoughtful review of the manuscript.

Access policy for JAMIA

All content published in JAMIA is deposited with PubMedCentral by the publisher but with varying embargo times. Authors/funders may pay an Unlocked fee of $2,000 to make the article free on the JAMIA website and PMC immediately on publication. Research funded by government and other recognised agencies is deposited with a 12 month embargo. All other content is deposited with a 36 month embargo.

The Journal of the American Medical Informatics Association is published for the American Medical Informatics Association by BMJ Publishing Group Ltd.